ERBB2 and breast carcinoma: The response rate and progression-free survival for the trastuzumab deruxtecan arm in this study implied that single-agent trastuzumab deruxtecan is as potent as pertuzumab- and trastuzumab-containing triplet chemotherapy, the current gold-standard for first-line treatment of advanced HER2-positive breast cancer [18].